Purchase Order 75N91018P00743
Award Date
9/14/18
Potential Completion Date
11/13/19
Potential Value
$631K
Federal Agency
National Cancer Institute
Awardee
Illumina, Inc.
Ultimate Awardee
Not listed
NAICS Category
334516 - Analytical Laboratory Instrument Manufacturing
PSC Category
6640 - Laboratory Equipment And Supplies
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92122, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $202,000.00 firm fixed price purchase order awarded by the National Cancer Institute (NCI), a civilian agency within the National Institutes of Health (NIH), to Illumina, Inc. for the provision of an Illumina NextSeq 500 sequencing system. The contract has no set-aside designation. Through past contract awards, Illumina has provided a range of genomic sequencing instruments, reagents, and support services to various federal agencies including the NIH, Centers for Disease Control and...
This firm fixed-price purchase order was awarded by the National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH), to Illumina, Inc. for the procurement of one (1) Illumina NextSeq 550 DX Sequencing System. The $281,764 contract supports the NCI's Comprehensive Oncologic Molecular Pathology and Sequencing Service (COMPASS) and has an ultimate completion date of September 6, 2024. The system must be capable of sequencing DNA libraries using in vitro diagnostic...
The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute (NCI) awarded a firm fixed-price purchase order to Illumina, Inc., a for-profit manufacturer of genomics sequencing systems and reagents, for the procurement of an Illumina NextSeq 550 sequencing system. The $266,475 award was made on May 24, 2019 with an August 22, 2019 completion date. This purchase will complement the NCI's existing Illumina NextSeq 500 and MiSeq instruments used by...
This is a firm fixed price delivery order contract awarded by the National Cancer Institute, a civilian agency within the Department of Health and Human Services, to Illumina, Inc., a for-profit manufacturer of genetic analysis instruments and reagents. The contract, valued at $81,640.80, is for the provision of NEXTSEQ 500/500 sequencing systems and related catalog items. The award has no set-aside designation. Illumina has previously provided sequencing systems and services to support...
This is a firm fixed price delivery order contract awarded by the National Institute of Environmental Health Sciences (NIEHS), a civilian agency, to Illumina, Inc., a manufacturer of genetic sequencing systems and reagents. The award, valued at $135,908.52, is for the provision of Illumina's NextSeq, NovaSeq, MiSeq, and iSeq sequencing platforms, along with accompanying reagents, consumables, sample preparation kits, sequencing chips, support plans, maintenance services, and bioinformatics...
This federal contract award is for the procurement of an Illumina NextSeq 2000 sequencing system by the National Cancer Institute, which is part of the National Institutes of Health (NIH) under the Department of Health and Human Services (HHS). The award, valued at $239,190.00, was issued on a firm fixed price basis to Illumina, Inc., a for-profit manufacturer of genetic and genomic analysis instruments and reagents. The contract did not have a set-aside designation. This award appears to be...
This is a Federal contract award to Illumina, Inc., a manufacturer of sequencing and array-based genomic analysis solutions, to provide a NextSeq 500 Sequencing System. The $239,875.00 firm fixed price contract was awarded on September 6, 2016 by the National Cancer Institute, a component of the National Institutes of Health, with a completion date of December 31, 2016. The contract does not have a set-aside designation. Illumina has extensive experience providing sequencing instruments,...
This is a firm fixed-price purchase order awarded by the Department of Health and Human Services National Institutes of Health National Cancer Institute to Illumina, Inc., a manufacturer of genetic sequencing instruments and consumables. The contract is for Illumina's NextSeq 500 Sequencing System Production Care comprehensive support plan, with a potential value of $145,851.23 and a completion date of January 31, 2023. Illumina has previously received awards from federal agencies like the...
This firm fixed-price delivery order was awarded by the National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services (HHS), to Illumina, Inc., a manufacturer of genetic sequencing instruments and reagents. The contract award, valued at $95,738.22, is for the provision of 20024908 NEXTSEQ 500/550 HIGH OUTPUT KIT V2.5 (300 CYCLES), a sequencing consumable product. The award has no set-aside designation and is not associated with a larger contract vehicle....
This is a $28,749.60 firm-fixed-price delivery order contract awarded by the National Cancer Institute (NCI) to Illumina, Inc., a manufacturer of sequencing and array-based genomic analysis solutions. The contract is for the provision of laboratory equipment and supplies, with no set-aside designation. Through this award, Illumina will provide the NCI with a range of its NextSeq, NovaSeq, MiSeq, and iSeq sequencing systems, as well as accompanying reagents, consumables, sample prep kits,...